The company has eliminated an organizational layer to shorten the decision-making process in the US operations and to create closer collaboration between global and local functions.
The role as CEO of Oncopeptides, Inc. will no longer be a designated company function and as a consequence, Joseph Horvat, President of North America and CEO of Oncopeptides Inc., will leave the company.
Mohamed Ladha, current Head of US Commercial Operations, will become General Manager of the US Business Unit and a member of the global Leadership Team of Oncopeptides AB.
“I am very pleased that Mohamed, who has extensive commercial leadership and launch experience within oncology, assumes the new position as General Manager of the US Business Unit, and that we now will be able to fully leverage our global resources,” says Marty J Duvall, CEO of Oncopeptides. “I would also like to recognize the achievements that Joe and his leadership team has accomplished over the last nine months in building the US operations. On behalf of the entire company, I thank Joe for his contributions and wish him well in his future endeavors.”
A potential launch of melflufen around year end 2020
Recently the US Food and Drug Administration, FDA, granted priority review for Oncopeptides´ New Drug Application seeking approval of melflufen in combination with dexamethasone for the treatment of adult patients with triple-class refractory multiple myeloma patients. The submission is based on the results from the phase 2 study HORIZON. The FDA has set a PDUFA-date (Prescription Drug User Fee Act), which is the target date for their review of the New Drug Application, to February 28, 2021.
As previously communicated, the company prepares for a potential launch of melflufen around year end 2020.
Photo of Mohamed Ladha, General Manager, US Business Unit Oncopeptides